通过皮肤冠状动脉干预 (LEAST) 进行的ST升高心肌梗塞患者中低剂量阿司匹林评估的研究方案:多中心,双盲,随机对照临床试验
Wen Zheng1, Zhao-Ting Gong1, Hai-Yan Qian1
1Center for Coronary Artery Disease, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Annals of medicine
|November 24, 2025
概括
这项研究调查了中国ST升高心肌梗塞 (STEMI) 患者的低剂量与标准剂量阿司匹林对抗双重抗血小板治疗. 这些发现旨在优化阿司匹林的维持剂量,以提高东亚人群的疗效和安全性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 使用阿司匹林和提卡格勒勒的双重抗血小板治疗 (DAPT) 是ST升高心肌梗塞 (STEMI) 的标准.
- 最佳的阿司匹林维持剂量仍在争论中,特别是在出血敏感度较高的东亚人群中.
- 标准的DAPT疗法可能会增加特定种族群体的出血风险.
研究的目的:
- 为了确定在接受提卡格的中国STEMI患者中最佳的阿司匹林维持剂量.
- 评估不同剂量阿司匹林的缺血事件和出血风险之间的平衡.
- 为针对急性冠状动脉综合征的特定人群的抗血栓策略提供信息.
主要方法:
- 低剂量阿司匹林评估 (LEAST) 试验是一项多中心,随机,双盲,安慰剂受控的研究.
- 3612名中国STEMI患者经过皮肤冠状动脉干预后将被随机选择.
- 低剂量阿司匹林 (50毫克/天) 与标准剂量阿司匹林 (100毫克/天) 与提卡格雷勒 (90毫克/天两次) 的比较.
主要成果:
- 主要终点:12个月内心脏病死亡,心脏病发作,中风或再血管化 (非劣势) 的综合结果.
- 二级终点:学术研究联盟 (BARC) 的出血3或5型出血 (优越性).
- 层次测试确保只有在确立缺血安全的情况下,才会声称出血益处.
结论:
- 该LEAST试验将为中国STEMI患者的阿司匹林剂量提供关键证据.
- 这些发现可能会为东亚人群量身定制的抗血栓治疗策略.
- 结果可能会影响未来关于急性冠状动脉综合征管理的指导方针建议.
关键词:
双重抗血小板疗法 双重抗血小板疗法东亚地区的东亚地区.ST升高心肌梗塞的心脏病发作阿司匹林是一种阿司匹林.发生出血,出血.通过皮肤进行冠状动脉干预.协议 协议 协议 协议 协议随机对照试验是随机对照试验.这就是Ticagrelor.更多相关视频
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.7K
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
3.7K
相关概念视频
01:28Acute Coronary Syndrome IV: Interprofessional Care
203
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
203
01:30Acute Coronary Syndrome I: Introduction
744
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
744
01:30Acute Coronary Syndrome III: Diagnostic Studies
200
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
200
01:28Cardiac Catheterization I: Pre-Procedure Overview
1.0K
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
1.0K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
329
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
329
01:26Angina IV: Management
222
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
222